Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. - Archive ouverte HAL Access content directly
Journal Articles New England Journal of Medicine Year : 2012

Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

(1) , (2) , (3) , (4) , (5) , (6, 7) , (8) , (9) , (10) , (11) , (12) , , , , (13) , , (14) , , , , , (15, 16) , (13) ,
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Denis Caillot
  • Function : Author
Philippe Moreau
Laurent Garderet
Serge Leyvraz
  • Function : Author
Marie-Christiane Vekemans
  • Function : Author
Laurent Voillat
  • Function : Author
Brigitte Pegourie
  • Function : Author
Murielle Roussel
  • Function : Author
Xavier Leleu
  • Function : Author
Claire Mathiot
  • Function : Author
Catherine Payen
  • Function : Author
Non Renseigné
  • Function : Author

Abstract

BACKGROUND: High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy after transplantation. METHODS: We randomly assigned 614 patients younger than 65 years of age who had nonprogressive disease after first-line transplantation to maintenance treatment with either lenalidomide (10 mg per day for the first 3 months, increased to 15 mg if tolerated) or placebo until relapse. The primary end point was progression-free survival. RESULTS: Lenalidomide maintenance therapy improved median progression-free survival (41 months, vs. 23 months with placebo; hazard ratio, 0.50; P<0.001). This benefit was observed across all patient subgroups, including those based on the β(2)-microglobulin level, cytogenetic profile, and response after transplantation. With a median follow-up period of 45 months, more than 70% of patients in both groups were alive at 4 years. The rates of grade 3 or 4 peripheral neuropathy were similar in the two groups. The incidence of second primary cancers was 3.1 per 100 patient-years in the lenalidomide group versus 1.2 per 100 patient-years in the placebo group (P=0.002). Median event-free survival (with events that included second primary cancers) was significantly improved with lenalidomide (40 months, vs. 23 months with placebo; P<0.001). CONCLUSIONS: Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma. Four years after randomization, overall survival was similar in the two study groups. (Funded by the Programme Hospitalier de Recherche Clinique and others; ClinicalTrials.gov number, NCT00430365.).
Not file

Dates and versions

hal-00852275 , version 1 (20-08-2013)

Identifiers

Cite

Michel Attal, Valerie Lauwers-Cances, Gerald Marit, Denis Caillot, Philippe Moreau, et al.. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.. New England Journal of Medicine, 2012, 366 (19), pp.1782-91. ⟨10.1056/NEJMoa1114138⟩. ⟨hal-00852275⟩
289 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More